Drimva

GSK

Sr. Director, MASH/ALD Brand Lead & Pipeline

$205K–$341K

USA - North Carolina - Durham +7 · Hybrid (Remote & On-site) · Director · Full-time · Posted Oct 28, 2026

Location
USA - North Carolina - Durham
Washington DC
USA - Pennsylvania - Philadelphia
USA - California - Los Angeles
USA - Illinois - Chicago
USA - New York - New York
USA - Texas - Dallas
USA - Massachusetts - Boston
Experience
Minimum 10 years; no alternatives stated.
Education
Bachelor's degree required; advanced degree strongly preferred (e.g., MBA, master's degree, or equivalent).

About the job

Leads U.S. commercial strategy for MASH/ALD assets and the broader Hepatology/Immunology pipeline, from early development through launch readiness and lifecycle management.

What you'll do

  • Own MASH/ALD commercial strategy and lead cross-functional planning and launch-readiness activities.
  • Set U.S. pipeline and portfolio priorities, market assessments, positioning, and stage-gate recommendations.
  • Represent U.S. commercial perspectives in global governance and guide investment, go-to-market, and portfolio decisions.

What they ask for

  • Bachelor's degree in Marketing, Business, Life Sciences, or a related field.
  • At least 10 years of pharmaceutical, biotech, or healthcare experience, including Hepatology/Immunology experience in at least one relevant function.
  • In-line brand marketing or management experience, experience with HCP- or patient-administered specialty medicines, and ownership of commercial strategy for pipeline and/or in-line assets.
  • Cross-functional initiative leadership, executive-level strategic discussions grounded in data, budget and investment management, and direct people leadership.

Nice to have

  • Advanced degree (e.g., MBA, master's degree, or equivalent).
  • Hepatology/Immunology marketplace expertise and leadership in portfolio, pipeline, or new product strategy, including go-to-market models or P&L optimization.

Pay

USD 204,750 to USD 341,250 annual base salary

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 6, 2026 (UTC)